- Conditions
- Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Cholinergic Agents, Neurotransmitter Agents, incobotulinumtoxinA, Botulinum Toxins, Type A
- Interventions
- NT 201, NT 201 Placebo
- Drug
- Lead sponsor
- Merz North America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 27
- States / cities
- Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–42
of 18
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Atropine Bioequivalence
- Interventions
- Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
- Drug
- Lead sponsor
- Biomedical Advanced Research and Development Authority
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Lumbar Spinal Fusions
- Interventions
- Pregabalin 150 mg, Placebo
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Haematologic Neoplasms
- Interventions
- AZD2962
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Miami, Florida • Tampa, Florida • Houston, Texas
- Conditions
- Morphine, Analgesics, Analgesics, Opioid, Peripheral Nervous System Agents
- Interventions
- Saline, Bupivacaine, Dexamethasone
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neuralgia, Shingles, Peripheral Nervous System Disease
- Interventions
- REN-1654
- Drug
- Lead sponsor
- Renovis
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 16
- States / cities
- Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more
- Conditions
- COVID-19-Induced Parosmia
- Interventions
- Stellate Ganglion Block, Placebo Sham Injection
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Molecular Mechanisms of Pharmacological Action, Antiviral Agents, Anti-infective Agents, Analgesics, Non-narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents
- Interventions
- CYNK001-IV, CYNK001-IT
- Biological
- Lead sponsor
- Celularity Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Icatibant (30 mg)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Postoperative Pain
- Interventions
- CR845, Placebo
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 18
- States / cities
- Florence, Alabama • Mobile, Alabama • Montgomery, Alabama + 14 more
- Conditions
- Proctitis, Proctosigmoiditis
- Interventions
- Budesonide, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 62
- States / cities
- Dothan, Alabama • Mesa, Arizona • Tucson, Arizona + 59 more
- Conditions
- Neonatal Abstinence Syndrome
- Interventions
- Clonidine, Morphine
- Drug
- Lead sponsor
- Henrietta Bada
- Other
- Eligibility
- 12 Hours to 7 Days
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Eosinophilic Esophagitis
- Interventions
- APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
- Drug · Procedure
- Lead sponsor
- Ellodi Pharmaceuticals, LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 59
- States / cities
- Dothan, Alabama • Mobile, Alabama • Scottsdale, Arizona + 54 more
- Conditions
- Endometrial Cancer
- Interventions
- Sapanisertib, Serabelisib, Paclitaxel
- Drug
- Lead sponsor
- Faeth Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 18
- States / cities
- La Jolla, California • San Francisco, California • Miami Beach, Florida + 15 more
- Conditions
- Depression, Unipolar
- Interventions
- Intravenous Ketamine
- Drug
- Lead sponsor
- Jay Fournier
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Acute Pain
- Interventions
- CR845, Placebo
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years to 60 Years · Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 12
- States / cities
- Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 7 more
- Conditions
- Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents, Analgesics, Peripheral Nervous System Agents, Physiological Effects of Drugs, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Central Nervous System Depressants, Excitatory Amino Acid Antagonists, Excitatory Amino Acid Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Ketamine, Depression, Unipolar, Depressive Symptoms, Treatment Resistant Depression, Major Depressive Disorder, Depression, Bipolar
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine, Peripheral Nervous System Agents, Central Nervous System Depressants, Neurotransmitter Agents, Anti-Inflammatory Agents, Physiological Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptoms
- Interventions
- VTS-K
- Drug
- Lead sponsor
- Theresa Jacob, PhD, MPH
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Brooklyn, New York